KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Cash & Equivalents (2016 - 2026)

Merck has reported Cash & Equivalents over the past 18 years, most recently at $5.3 billion for Q1 2026.

  • Quarterly Cash & Equivalents fell 38.27% to $5.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.3 billion through Mar 2026, down 38.27% year-over-year, with the annual reading at $14.6 billion for FY2025, 9.99% up from the prior year.
  • Cash & Equivalents was $5.3 billion for Q1 2026 at Merck, down from $14.6 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $18.2 billion in Q3 2025 and troughed at $5.3 billion in Q1 2026.
  • The 5-year median for Cash & Equivalents is $9.7 billion (2022), against an average of $10.1 billion.
  • Year-over-year, Cash & Equivalents crashed 46.11% in 2023 and then soared 99.72% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $12.7 billion in 2022, then crashed by 46.11% to $6.8 billion in 2023, then surged by 93.57% to $13.2 billion in 2024, then grew by 9.99% to $14.6 billion in 2025, then crashed by 63.43% to $5.3 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Cash & Equivalents are $5.3 billion (Q1 2026), $14.6 billion (Q4 2025), and $18.2 billion (Q3 2025).